Comments*

 
  • Clinical Medicine

  • Events 

    Thursday, October 9, 2014 | 8:00 AM - 4:00 PM

    Targeting Key Vulnerabilities in Pancreatic Cancer

    Keynote Speakers: Neesha Dhani (Princess Margaret Hospital, Toronto), Steven D. Leach (Memorial Sloan Kettering Cancer Center)
    Speakers: Gregory Beatty (University of Pennsylvania Perelman School of Medicine), Mikala Egeblad (Cold Spring Harbor Laboratory), Douglas T. Fearon (Weill Cornell Medical College and Cold Spring Harbor Laboratory), Costas A. Lyssiotis (Weill Cornell Medical College ), George Miller (NYU Langone Medical Center), Michael Ports (Gilead Sciences)

    Pancreatic cancer patients currently have limited therapeutic options. This symposium explores breakthroughs in the pathogenesis and progression of pancreatic cancer, and efforts to exploit key vulnerabilities for novel therapeutic interventions.

    Friday, October 10, 2014 | 8:00 AM - 3:15 PM

    New Frontiers in the Neurobiology of Mental Illness

    Sold Out
    Keynote Speaker: The Honorable Patrick J. Kennedy
    Former United States Representative, Rhode Island; One Mind for Research; Kennedy Forum

    This conference will explore the translation of recent breakthroughs in neuroscience into therapies for the more than twenty-five percent of Americans suffering from mental illnesses such as schizophrenia, depression, fear and anxiety disorders, autism, and other psychiatric disorders. A keynote lecture by The Honorable Patrick J Kennedy will address strategies to simultaneously abolish the stigma surrounding mental illness in order to fully realize the potential of these new treatments to improve mental health.

    Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM

    Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

    Speaker: Michael S. Conte (University of California-San Francisco), Milan Fiala (David Geffen School of Medicine at UCLA), Gabrielle Fredman (Columbia University), Bruce Levy (Harvard University, Brigham and Women's Hospital), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Harvard Medical School), Mauro Perretti (Queen Mary University of London), Charles N. Serhan (Brigham & Women's Hospital, Harvard Medical School), Patricia J. Sime (University of Rochester School of Medicine), Rudolph E. Tanzi (Massachusetts General Hospital)

    Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.

    Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM

    Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

    Speakers: Matthew D. Breyer (Eli Lilly, Indianapolis, IN), Frank C. Brosius (University of Michigan Medical School, Ann Arbor, MI), Benjamin D. Humphreys (Harvard Institutes of Medicine, Boston, MA), Matthias Meier (F. Hoffmann-LaRoche Ltd, Basel, Switzerland), Shahnaz Shahinfar (The Children's Hospital of Philadelphia, Philadelphia, PA), Katalin Susztak (University of Pennsylvania, Philadelphia, PA), Aliza Thompson (US Food & Drug Administration, Silver Spring)

    Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.

    Tuesday, January 27, 2015 | 8:30 AM - 4:30 PM

    Growing Pains: The Future of Cytokines as Immunotherapies for Oncology, Infection and Inflammatory Disease

    Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School)
    Speakers: Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle MA), Dario Neri (Philogen, Zurich, Switzerland), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology)

    Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.

  • Past Events

    Tuesday, September 30, 2014 | 8:30 AM - 5:00 PM

    Elucidating GPCR Functional Selectivity: Novel Opportunities for Drug Development

    Keynote Speaker: Nobel Laureate Robert J. Lefkowitz (Duke University Medical Center)
    Speakers: John A. Allen (Pfizer), Laura Bohn (The Scripps Research Institute - Florida), Marc G. Caron (Duke University Medical Center), Jonathan A. Javitch (Columbia University and New York State Psychiatric Institute), Terry Kenakin (University of North Carolina School of Medicine), Bryan L. Roth (University of North Carolina School of Medicine), JoAnn Trejo (University of California, San Diego), Jonathan D. Violin (Trevena Inc.)

    Hear academic, industry, basic and translational researchers, including Nobel Laureate Robert Lefkowitz (Duke University Medical Center) and discuss the development of functionally selective GPCR-biased ligands for CV and CNS disease drug discovery.

    Thursday, June 26, 2014 | 7:45 AM - 6:00 PM

    Demyelination and Remyelination: From Mechanism to Therapy

    Keynote Speaker: Robin Franklin (Wellcome Trust – MRC Cambridge Stem Cell Institute, University of Cambridge)

    This translational conference will highlight biological and clinical findings in myelin development, new techniques for brain imaging and for screening molecular targets, and novel therapeutics that promote remyelination.

    Tuesday, May 20, 2014 | 8:30 AM - 5:00 PM

    Hot Technologies for Developing Next-Gen Biologics

    Speakers: Timothy Charlebois (Pfizer), David King (AnaptysBio Inc.), William M. Pardridge (Brain Research Institute, UCLA), Steven J. Projan (MedImmune), Sachdev Siddhu (University of Toronto), E. Sally Ward (UT Southwestern), Patrick C. Wilson (The University of Chicago), K. Dane Wittrup (Massachusetts Institute of Technology)

    New technologies are pivotal in developing next-generation biologics. This symposium highlights novel technologies in the discovery of new biologics, elucidating in vivo mechanisms of therapeutic proteins, and manufacturing and delivery processes.

    Friday, May 9, 2014 | 8:00 AM - 4:00 PM

    The Biology of Aging: Novel Drug Targets for Neurodegenerative Disease

    Speakers: Carmela R. Abraham (Boston University School of Medicine), Eric H. Baehrecke (University of Massachusetts Medical School), Nir Barzilai (Albert Einstein College of Medicine), Jerry R. Colca (Metabolic Solutions Development Company), Brendan D. Manning (Harvard School of Public Health), Beth Stevens (Harvard Medical School), D. Martin Watterson (Northwestern University Feinberg School of Medicine), Haung Yu (Columbia University), Jeffrey W. Kelly (The Scripps Research Institute), Richard I. Morimoto (Northwestern University)

    Age is the major risk factor for Alzheimer's disease, and key pathways in aging biology offer targets for novel drugs. Explore recent advances in the science of aging and innovative drug discovery for Alzheimer's and other neurodegenerative diseases.

  • Publications 

    eBriefing

    Demyelination and Remyelination: From Mechanism to Therapy

    Keynote Speaker: Robin Franklin (Wellcome Trust – MRC Cambridge Stem Cell Institute, University of Cambridge)

    This eBriefing highlights biological and clinical findings in remyelination. It also features new techniques for imaging myelin and screening molecular targets, as well as therapeutics that promote remyelination.

    Annals

    Antimicrobial Therapeutics Reviews: Infectious Diseases of Current and Emerging Concern

    Edited by Karen Bush (Indiana University)

    The forth installment of this annual reviews series discusses the impact of infectious diseases (including carbapenem-resistant Enterobacteriaceae, tuberculosis, typhoid, influenza, and dengue) on the health of populations worldwide.

    Volume 1323

    Annals

    Annals Reports

    Edited by Annals of the New York Academy of Sciences editorial staff

    This Annals volume presents three meeting reports: (1) Production and supply of high-quality food protein for human consumption: sustainability, challenges, and innovations; (2) Clinical and economic outcomes of nutrition interventions across the continuum of care; and (3) Antibody–drug conjugates: an emerging modality for the treatment of cancer.

    Volume 1321

    eBriefing

    The Biology of Aging: Novel Drug Targets for Neurodegenerative Disease

    Organizers: Howard Fillit (Alzheimer's Drug Discovery Foundation), Kevin J. Lee (Lawrence Ellison Foundation), and Jennifer Henry (The New York Academy of Sciences)

    This eBriefing explores advances in the science of aging and in drug discovery for Alzheimer's and other neurodegenerative diseases.

  • Podcasts

    Podcast
    July 30, 2010

    Oxidative Stress

    Foods high in antioxidants are believed to fight oxidative stress. But what is oxidative stress? Two scientists from a recent NYAS conference break it down and discuss whether antioxidants have superpowers.

    Download (12 MB, 00:18:37)
    Podcast
    April 2, 2010

    More than a Yogurt Cup

    Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.

    Download (14 MB, 00:21:21)
    Podcast
    January 29, 2010

    ADHD and the Brain

    Neuropsychologist Jeffrey Halperin is using behavioral therapy on preschoolers with attention deficit hyperactivity disorder (ADHD). He hopes to train their brains to develop in new ways and if effective, his therapies could offer permanent, drug-free treatment for the disorder.

    Download (11 MB, 00:17:30)
    Podcast
    January 15, 2010

    Feeling the Light

    Researchers at Harvard have discovered why the headaches of some migraine sufferers worsen when the person is exposed to light. Rami Burstein, the study's senior author, explains what's happening in the brain, and how they made the breakthrough.

    Download (15 MB, 00:22:48)
  • Translational Medicine Initiative

    Macy FoundationThe Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.

    Learn more at www.nyas.org/TransMed.